Literature DB >> 19235577

Evaluation of possible prognostic factors of fulminant acute disseminated encephalomyelitis (ADEM) on magnetic resonance imaging with fluid-attenuated inversion recovery (FLAIR) and diffusion-weighted imaging.

F Y Donmez1, H Aslan, M Coskun.   

Abstract

BACKGROUND: Acute disseminated encephalomyelitis (ADEM) may be a rapidly progressive disease with different clinical outcomes.
PURPOSE: To investigate the radiological findings of fulminant ADEM on diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) images, and to correlate these findings with clinical outcome.
MATERIAL AND METHODS: Initial and follow-up magnetic resonance imaging (MRI) scans in eight patients were retrospectively evaluated for distribution of lesions on FLAIR images and presence of hemorrhage or contrast enhancement. DWI of the patients was evaluated as to cytotoxic versus vasogenic edema. The clinical records were analyzed, and MRI results and clinical outcome were correlated.
RESULTS: Four of the eight patients died, three had full recovery, and one had residual cortical blindness. The distribution of the hyperintense lesions on FLAIR sequence was as follows: frontal (37.5%), parietal (50%), temporal (37.5%), occipital (62.5%), basal ganglia (50%), pons (37.5%), mesencephalon (37.5%), and cerebellum (50%). Three of the patients who died had brainstem involvement. Two patients had a cytotoxic edema, one of whom died, and the other developed cortical blindness. Six patients had vasogenic edema: three of these patients had a rapid progression to coma and died; three of them recovered.
CONCLUSION: DWI is not always helpful for evaluating the evolution or predicting the outcome of ADEM. However, extension of the lesions, particularly brainstem involvement, may have an influence on the prognosis.

Entities:  

Mesh:

Year:  2009        PMID: 19235577     DOI: 10.1080/02841850902736617

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  8 in total

Review 1.  A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.

Authors:  Christopher Eckstein; Shiv Saidha; Michael Levy
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

2.  Isolated brain stem lesion in children: is it acute disseminated encephalomyelitis or not?

Authors:  G Alper; G Sreedher; G Zuccoli
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-05       Impact factor: 3.825

3.  Vasogenic edema characterizes pediatric acute disseminated encephalomyelitis.

Authors:  Giulio Zuccoli; Ashok Panigrahy; Gayathri Sreedher; Ariel Bailey; Ernest John Laney; Luca La Colla; Gulay Alper
Journal:  Neuroradiology       Date:  2014-05-23       Impact factor: 2.804

4.  A Case of ADEM Mimicking Cerebral Adrenoleukodystrophy Based on Supratentorial MRI Findings.

Authors:  Mehmet Beyazal; Özkan Ünal; Sanem Yilmaz; Aydın Bora
Journal:  Noro Psikiyatr Ars       Date:  2014-03-01       Impact factor: 1.339

5.  Comparative brain stem lesions on MRI of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis.

Authors:  Zhengqi Lu; Bingjun Zhang; Wei Qiu; Zhuang Kang; Liping Shen; Youming Long; Junqi Huang; Xueqiang Hu
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

6.  Refractory Fulminant Acute Disseminated Encephalomyelitis (ADEM) in an Adult.

Authors:  Federico Rodríguez-Porcel; Alejandro Hornik; Jordan Rosenblum; Ewa Borys; José Biller
Journal:  Front Neurol       Date:  2014-12-23       Impact factor: 4.003

7.  Bilateral thalamic lesions in a patient with probable acute disseminating encephalomyelitis: a case report.

Authors:  Yiming Zheng; Wei Zhang; Hongjun Hao; Feng Gao
Journal:  BMC Neurol       Date:  2020-07-01       Impact factor: 2.474

8.  Clinicoradiological and prognostic features of COVID-19-associated acute disseminated encephalomyelitis.

Authors:  J Oumerzouk; M Nabil; R Klevor; S Belasri; M Chraa; N Louhab; N Kissani
Journal:  Rev Neurol (Paris)       Date:  2021-11-27       Impact factor: 2.607

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.